ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder

BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a...